aoc 1001
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Oct 28, 2021 (NCT05027269)
Timeline
Indications
Studied for
- Diabetes Mellitus, Type 1 · Phase 3
- Genetic Diseases, Inborn · Phase 2
- Heredodegenerative Disorders, Nervous System · Phase 2
- Muscular Diseases · Phase 2
- Muscular Disorders, Atrophic · Phase 2
- Muscular Dystrophies · Phase 2
- Musculoskeletal Diseases · Phase 2
- Myotonia · Phase 3
- Myotonic Disorders · Phase 3
- Myotonic Dystrophy · Phase 3
- Nervous System Diseases · Phase 2
- Neurodegenerative Diseases · Phase 2
- Neuromuscular Diseases · Phase 2
Mechanism of action
- Transferrin receptor protein 1BINDING AGENT
TFRC binding agent
Chemistry & pharmacology
- Payload
- DMPK siRNA
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07008469 | Phase 3 | Jul 25, 2025 | Avidity Biosciences, Inc. |
| NCT06411288 | Phase 3 | May 30, 2024 | Avidity Biosciences, Inc. |
| NCT05479981 | Phase 2 | Aug 4, 2022 | Avidity Biosciences, Inc. |
| NCT05027269 | Phase 1/Phase 2 (Phase 2) | Oct 28, 2021 | Avidity Biosciences, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Avidity Biosciences, Inc. | For profit | 4 | 4 | 2 | 2021 |
1 organizations
Page 1 / 1